Kinase inhibitors

US9499535B2 · kind B2 · utility

Assignee

• Origenis GMBH · DE

Inventors

• Michael Thormann · Martinsried, DE
• Andreas Treml · Martinsried, DE
• Michael Almstetter · Martinsried, DE
• Roland Koestler · Martinsried, DE
• Nasser Yehia · Martinsried, DE

Key dates

• Filing date: Apr 23, 2012
• Grant date: Nov 22, 2016
• Expiry date: Mar 26, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel compounds of formula (I)that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases.